ICH Q3A: Impurities in New Drug Substances Explained
ICH Q3A(R2) establishes the framework for reporting, identifying, and qualifying impurities in new drug substances (APIs). The guideline classifies impurities as organic, inorganic, or residual solvents, and sets thresholds based on maximum daily dose: reporting thresholds as low as 0.03% for doses > 2 g/day, identification thresholds as low as 0.10% (for doses > 2 g/day), and qualification thresholds as low as 0.15% (for doses > 2 g/day). Impurities above these thresholds must be reported in specifications, structurally identified, and qualified for safety.
Key Takeaways
Key Takeaways
- ICH Q3A(R2) sets dose-dependent thresholds for reporting (0.03-0.05%), identification (0.10-0.20%), and qualification (0.15-1.0%) of impurities in new drug substances.
- Organic impurities are the primary focus; inorganic impurities defer to ICH Q3D and residual solvents defer to ICH Q3C.
- Clinical qualification (documented patient exposure at the proposed level) is often the most practical path and avoids the cost of dedicated nonclinical studies.
- ICH Q3A does not apply to biological/biotechnological products, peptides, oligonucleotides, radiopharmaceuticals, fermentation products, or herbal products.
- ICH Q3A(R2) — "Impurities in New Drug Substances" — is the internationally harmonized guideline that defines how impurities in new chemical entity drug substances must be classified, reported, identified, and qualified for regulatory submissions.
- Published in its current revision (R2) in October 2006, ICH Q3A applies to all new chemical entities submitted as NDAs, MAAs, and equivalent applications in ICH regions (United States, European Union, Japan, and ICH member countries). The guideline does not apply to drug substances used during clinical research stages, biological/biotechnological products, peptides, oligonucleotides, radiopharmaceuticals, fermentation products, herbal products, or crude products of animal or plant origin.
- Understanding ICH Q3A is foundational for CMC teams because every Module 3.2.S.3.2 (Impurities) section of a CTD submission must demonstrate compliance with these thresholds and requirements. Failure to adequately address impurities is one of the most common causes of FDA Information Requests and EMA Day 120 questions.
- In this guide, you'll learn:
- How ICH Q3A classifies impurities in new drug substances
- The threshold tables for reporting, identification, and qualification
- Analytical procedure requirements for impurity detection
- How to set specifications based on impurity data
- The decision trees for identification and qualification
- ---
Scope and Applicability
What ICH Q3A Covers
ICH Q3A addresses impurities in new drug substances that are synthesized by chemical processes. It applies to:
- New chemical entities (NCEs) intended for marketing authorization
- Impurities present in the drug substance at the time of filing
- Degradation products of the drug substance that arise during storage
What ICH Q3A Does Not Cover
| Excluded Category | Governing Standard |
|---|---|
| Drug products (finished dosage forms) | ICH Q3B(R2) |
| Biological/biotechnological products | ICH Q6B |
| Peptides and oligonucleotides | ICH Q6B or product-specific |
| Herbal products | Regional guidance |
| Crude products of animal/plant origin | Regional guidance |
| Fermentation products | Product-specific |
| Radiopharmaceuticals | Regional guidance |
| Clinical trial materials | ICH Q7 (GMP for APIs); thresholds are less stringent |
| Enantiomeric impurities | ICH Q6A (may be addressed) |
| Polymorphic forms | ICH Q6A |
| Mutagenic impurities | ICH M7 (additional, more stringent requirements apply) |
| Elemental impurities | ICH Q3D |
| Residual solvents (detailed limits) | ICH Q3C |
ICH Q3A thresholds apply in addition to ICH M7 requirements. A process impurity that is below Q3A reporting thresholds may still require control as a mutagenic impurity under ICH M7. Always conduct M7 assessment in parallel with Q3A compliance work.
Classification of Impurities
ICH Q3A divides impurities in drug substances into three categories:
1. Organic Impurities
Organic impurities arise from the manufacturing process or from degradation of the drug substance. They include:
| Subcategory | Examples | Source |
|---|---|---|
| Starting materials | Unreacted starting material carried through | Incomplete reaction |
| By-products | Structural isomers, ring-opened products | Side reactions during synthesis |
| Intermediates | Partially reacted intermediates | Incomplete conversion |
| Degradation products | Hydrolysis products, oxidation products | Chemical instability |
| Reagents and ligands | Catalysts, coupling agents | Incomplete removal |
| Process-related impurities | Impurities introduced by the synthetic route | Route-specific chemistry |
Organic impurities are the primary focus of ICH Q3A thresholds and are controlled through the reporting, identification, and qualification framework.
2. Inorganic Impurities
Inorganic impurities include:
| Type | Examples | Control |
|---|---|---|
| Reagents | Heavy metals from catalysts (Pd, Pt) | ICH Q3D (elemental impurities) |
| Processing aids | Filter aids, charcoal | Process-specific testing |
| Metal ions | From equipment contact (Fe, Ni, Cr) | ICH Q3D risk assessment |
| Salts | Inorganic salts from neutralization | Specification testing |
ICH Q3A acknowledges inorganic impurities but directs their specific control to ICH Q3D for elemental impurities and pharmacopeial methods for other inorganic contaminants.
3. Residual Solvents
Solvents used in the synthesis of drug substances are controlled per ICH Q3C. ICH Q3A references Q3C but does not establish independent residual solvent thresholds.
Threshold Tables
The core of ICH Q3A is the threshold system that determines when an impurity must be reported, structurally identified, or safety-qualified. Thresholds are based on the maximum daily dose of the drug substance.
Reporting Thresholds
An impurity above the reporting threshold must be reported in the drug substance specification and included in batch analysis data submitted to regulatory agencies.
| Maximum Daily Dose | Reporting Threshold |
|---|---|
| ≤ 2 g/day | 0.05% |
| > 2 g/day | 0.03% |
What "reporting" means:
- The impurity must appear in the specification (as a specified or unspecified impurity)
- Batch data showing impurity levels must be included in Module 3.2.S.4.4 (Batch Analyses)
- Impurities below the reporting threshold do not need to be individually listed
Identification Thresholds
An impurity above the identification threshold must be structurally characterized. Identification typically requires spectroscopic techniques (MS, NMR, IR) or comparison with authenticated reference standards.
| Maximum Daily Dose | Identification Threshold |
|---|---|
| ≤ 1 mg/day | 1.0% or 5 mcg TDI (total daily intake), whichever is lower |
| > 1 mg/day to 10 mg/day | 0.5% or 20 mcg TDI, whichever is lower |
| > 10 mg/day to 2 g/day | 0.2% or 2 mg TDI, whichever is lower |
| > 2 g/day | 0.10% |
TDI calculation:
The "whichever is lower" clause catches many CMC teams off guard for low-dose products. For a drug substance with a maximum daily dose of 0.5 mg, the identification threshold is 1.0% or 5 mcg TDI — but 5 mcg is 1.0% of 0.5 mg, so both criteria give the same answer. However, for a 5 mg dose, 0.5% = 25 mcg, and 20 mcg TDI = 0.4%, so the absolute TDI limit (20 mcg) applies, making the effective threshold 0.4%, not 0.5%.
Qualification Thresholds
An impurity above the qualification threshold must be qualified for safety through nonclinical or clinical studies, or justified through published literature, unless it has already been qualified.
| Maximum Daily Dose | Qualification Threshold |
|---|---|
| ≤ 10 mg/day | 1.0% or 50 mcg TDI, whichever is lower |
| > 10 mg/day to 100 mg/day | 0.5% or 200 mcg TDI, whichever is lower |
| > 100 mg/day to 2 g/day | 0.2% or 3 mg TDI, whichever is lower |
| > 2 g/day | 0.15% |
Combined Threshold Table
For quick reference, here are all three thresholds together:
| Max Daily Dose | Reporting | Identification | Qualification |
|---|---|---|---|
| ≤ 1 mg/day | 0.05% | 1.0% or 5 mcg TDI | 1.0% or 50 mcg TDI |
| > 1 to 10 mg/day | 0.05% | 0.5% or 20 mcg TDI | 1.0% or 50 mcg TDI |
| > 10 to 100 mg/day | 0.05% | 0.2% or 2 mg TDI | 0.5% or 200 mcg TDI |
| > 100 mg/day to 2 g/day | 0.05% | 0.2% or 2 mg TDI | 0.2% or 3 mg TDI |
| > 2 g/day | 0.03% | 0.10% | 0.15% |
Analytical Procedures
Requirements for Impurity Detection
ICH Q3A requires validated analytical procedures capable of detecting and quantifying impurities at or below the reporting threshold.
Method characteristics:
| Characteristic | Requirement | Reference |
|---|---|---|
| Specificity | Must separate drug substance peak from all known and potential impurities | ICH Q2(R2) |
| Detection limit | Must detect impurities below reporting threshold | Typically 50% of reporting threshold |
| Quantitation limit | Must accurately quantify at reporting threshold | Per ICH Q2(R2) methodology |
| Linearity | Demonstrated across the range from reporting threshold to 120% of specification | R² ≥ 0.999 recommended |
| Accuracy | Demonstrated by spiking at reporting, identification, and qualification levels | 80-120% recovery at low levels |
| Precision | Repeatability and intermediate precision | RSD ≤ 10% at specification level |
Common Analytical Techniques
| Technique | Application | Typical LOD |
|---|---|---|
| HPLC-UV | Primary method for organic impurities; gradient elution for broad screening | 0.01-0.05% |
| HPLC-MS | Identification of unknown impurities; structural characterization | 0.001-0.01% |
| GC | Volatile impurities; residual solvents | 1-10 ppm |
| ICP-MS | Elemental impurities (per Q3D) | 0.01-1 ppm |
| NMR | Structural elucidation of isolated impurities | N/A (confirmatory) |
| IR | Functional group identification | N/A (confirmatory) |
Unspecified Impurities
Any individual impurity above the reporting threshold but below the identification threshold is listed as an "unspecified impurity" in the specification. The specification should include:
- Individual unspecified impurity limit (at or below the identification threshold)
- Total impurities limit (sum of all individual impurities)
Specification Setting
Principles for Setting Impurity Limits
ICH Q3A establishes that impurity limits in drug substance specifications should be based on:
- Manufacturing capability: Batch-to-batch data from process development and validation batches
- Stability data: Impurity levels observed during stability studies (ICH Q1A)
- Safety qualification: Levels qualified through nonclinical or clinical studies
- Regulatory thresholds: ICH Q3A identification and qualification thresholds
The specification limit for each impurity should be set at the lower of:
- The qualified level (from safety studies or clinical exposure)
- A level justified by batch data and manufacturing capability
- The relevant threshold from ICH Q3A tables
Types of Impurities in Specifications
| Type | Definition | How Listed |
|---|---|---|
| Specified identified impurity | Impurity above identification threshold with known structure | Listed by name; individual acceptance criterion |
| Specified unidentified impurity | Impurity above identification threshold without known structure (should be identified) | Listed by relative retention time (RRT); individual acceptance criterion |
| Unspecified impurity | Any individual impurity below identification threshold | Blanket criterion: "any unspecified impurity NMT X%" |
| Total impurities | Sum of all individual impurities | Single acceptance criterion for the total |
Specification Example
For a drug substance with maximum daily dose of 500 mg:
| Impurity | Type | Acceptance Criterion | Basis |
|---|---|---|---|
| Impurity A (identified) | Specified, identified | NMT 0.20% | Qualified in nonclinical studies |
| Impurity B (identified) | Specified, identified | NMT 0.15% | Qualified by clinical exposure |
| RRT 0.85 (unidentified) | Specified, unidentified | NMT 0.10% | Below identification threshold; monitor |
| Any unspecified impurity | Unspecified | NMT 0.10% | ICH Q3A identification threshold |
| Total impurities | Total | NMT 1.0% | Based on batch data and qualification |
Decision Trees for Identification and Qualification
Identification Decision Tree
ICH Q3A provides a decision tree for determining when structural identification of an impurity is required:
Acceptable identification approaches:
| Approach | When Acceptable | Documentation |
|---|---|---|
| Comparison with reference standard | Authenticated reference available; retention time + spectral match | Chromatographic comparison data |
| Spectroscopic characterization | Novel impurity; no reference standard | MS, NMR, IR data with structural assignment |
| Inference from synthetic route | Process-related impurity with predictable structure | Chemical rationale + confirmatory data |
| Degradation pathway knowledge | Degradation product with known mechanism | Forced degradation data + spectral confirmation |
Qualification Decision Tree
When an impurity exceeds the qualification threshold, the following decision tree applies:
Qualification options:
| Option | Requirements | Typical Timeline |
|---|---|---|
| Published literature | Adequate published safety data at the relevant level | Immediate |
| Clinical qualification | Documented exposure in clinical trials at the proposed level; adequate safety database | Batch analysis from clinical supplies needed |
| Nonclinical qualification | General toxicology study at adequate exposure margin; genotoxicity battery | 6-12 months for study conduct |
| Reduction to qualified level | Process modification to reduce impurity below qualification threshold | Variable; depends on process development |
Clinical qualification is often the most practical path for process impurities observed late in development. If clinical trial batches contained the impurity at or above the proposed specification limit and the safety database shows no attributable adverse events, this constitutes clinical qualification. Always retain certificates of analysis for clinical batches — this data is required to support clinical qualification arguments.
Relationship to Other ICH Guidelines
| Guideline | Relationship to Q3A |
|---|---|
| ICH Q3B(R2) | Addresses degradation products in drug products; builds on Q3A principles for the finished dosage form |
| ICH Q3C(R8) | Specifically addresses residual solvents; Q3A references Q3C for solvent limits |
| ICH Q3D(R1) | Addresses elemental impurities; replaced the inorganic impurity testing referenced in Q3A |
| ICH M7(R1) | Addresses mutagenic impurities; additional, more stringent requirements overlay Q3A thresholds |
| ICH Q1A/Q1B | Stability testing; degradation products observed in stability studies fall under Q3A thresholds |
| ICH Q2(R2) | Analytical validation; Q3A requires validated methods per Q2 principles |
| ICH Q6A | Specifications; Q3A informs how impurity specifications are set in Q6A |
Key Takeaways
References
Key Takeaways
- 1. Three threshold types: Reporting (lowest), identification (intermediate), and qualification (highest). All are based on maximum daily dose of the drug substance.
- 2. Dose-dependent thresholds: Lower-dose products have more stringent percentage thresholds but also have absolute amount (TDI) cutoffs that may be more permissive. Always calculate both and apply whichever is lower.
- 3. Organic impurities are the primary focus: Inorganic impurities defer to ICH Q3D, residual solvents defer to ICH Q3C, and mutagenic impurities require additional ICH M7 assessment.
- 4. Analytical methods must reach reporting threshold sensitivity: The validated impurity method must detect impurities at or below the reporting threshold (0.05% for most products, 0.03% for > 2 g/day dose).
- 5. Qualification can be clinical or nonclinical: Clinical qualification (documented patient exposure at the proposed level) is often the most practical path. Retain certificates of analysis for all clinical batches.
- 6. Specification setting integrates multiple data sources: Batch data, stability data, qualified levels, and ICH Q3A thresholds all inform the final specification. The limit is set at the most conservative justified level.
- 7. ICH Q3A does not stand alone: Always evaluate impurities under Q3A in conjunction with M7 (mutagenic), Q3C (solvents), and Q3D (elemental). A single impurity may trigger requirements under multiple guidelines.
- ---
- ICH Q3A(R2): Impurities in New Drug Substances (October 2006)
- ICH Q3B(R2): Impurities in New Drug Products (June 2006)
- ICH Q3C(R8): Residual Solvents (April 2021)
- ICH Q3D(R1): Guideline for Elemental Impurities (March 2019)
- ICH M7(R1): Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals (March 2017)
- ICH Q2(R2): Validation of Analytical Procedures (November 2022)
- ICH Q6A: Specifications — Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products (October 1999)
- ICH Q1A(R2): Stability Testing of New Drug Substances and Products (February 2003)